CLD-101 is a novel stem cell-based treatment that delivers oncolytic viruses to tumors, which may benefit patients with newly ...

A study of long-term care facilities found residents with penicillin allergies were 95% less likely to receive beta-lactam antibiotics.

Results from the REVISIT trial show aztreonam-avibactam had similar cure rates as meropenem in patients with serious ...

New study shows that the lengths of menstrual cycles, follicular phases (before egg release) and luteal phases (after ovulation) are all variable. The luteal phase is importantly more variable than ...

Yufei Liu, MD, PhD, discussed the importance of careful data interpretation to accurately assess the efficacy of new ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

KaliVir Immunotherapeutics has dosed the first subject in a Phase I/Ib clinical trial for its new oncolytic immunotherapy, ...

Recce has successfully dosed half of target patients with RECCE 327 in its Phase 2 trial for Acute Bacterial Skin Infections.

More research on clinical meaningfulness is on the way, according to Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute and author of Investigating the ...

Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases –– Cardiovascular Scientific ...

Nurix Therapeutics offers promising targeted protein degradation treatments for cancer and autoimmune diseases. Find out what ...